Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep;43(9):532-535.

Dupilumab (Dupixent): An Interleukin-4 Receptor Antagonist for Atopic Dermatitis

Daniella D'Ippolito, Michele Pisano

Dupilumab (Dupixent): An Interleukin-4 Receptor Antagonist for Atopic Dermatitis

Daniella D'Ippolito et al. P T. 2018 Sep.

Abstract

Dupilumab (Dupixent) for atopic dermatitis.

PubMed Disclaimer

Conflict of interest statement

Disclosure: The authors report no commercial or financial interests in regard to this article.

Figures

Figure 1
Figure 1
Dupilumab Device
See this image and copyright information in PMC

References

    1. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(suppl 1):8–16. - PubMed
    1. Sanofi US, Regeneron Pharmaceuticals. The science: understanding what’s underneath. Eczema Exposed. 2017. [Accessed July 2018]. Available at: www.eczemaexposed.com/understanding-eczema.
    1. Weidinger S, Novak N. Atopic dermatitis. The Lancet. 2016;387:1109–1122. - PubMed
    1. Irvine A, McLean I, Leung D. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011;365:1315–1327. - PubMed
    1. Kim K. Influences of environmental chemicals on atopic dermatitis. Toxicological Research. 2015;31(2):89–96. - PMC - PubMed

LinkOut - more resources